MX2021009570A - Substituted bicyclic compounds as farnesoid x receptor modulators. - Google Patents

Substituted bicyclic compounds as farnesoid x receptor modulators.

Info

Publication number
MX2021009570A
MX2021009570A MX2021009570A MX2021009570A MX2021009570A MX 2021009570 A MX2021009570 A MX 2021009570A MX 2021009570 A MX2021009570 A MX 2021009570A MX 2021009570 A MX2021009570 A MX 2021009570A MX 2021009570 A MX2021009570 A MX 2021009570A
Authority
MX
Mexico
Prior art keywords
compounds
farnesoid
receptor modulators
substituted bicyclic
bicyclic compounds
Prior art date
Application number
MX2021009570A
Other languages
Spanish (es)
Inventor
Kandhasamy Sarkunam
Susheel Jethanand Nara
Srinivas Cheruku
Rishikesh Narayan
Dean A Wacker
Firoz Ali Jaipuri
Srinivas Jogi
Subba Reddy Bandreddy
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX2021009570A publication Critical patent/MX2021009570A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

Disclosed are compounds of Formula (I): or a stereoisomer, a tautomer, or a salt or solvate thereof, wherein Q is C2-6 alkenyl or C2-6 alkynyl, each substituted with zero to 2 R1; and the other variables are as defined herein. These compounds modulate the activity of farnesoid X receptor (FXR), for example, as agonists. Also disclosed are pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.
MX2021009570A 2019-02-15 2020-02-14 Substituted bicyclic compounds as farnesoid x receptor modulators. MX2021009570A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962806402P 2019-02-15 2019-02-15
PCT/US2020/018210 WO2020168148A1 (en) 2019-02-15 2020-02-14 Substituted bicyclic compounds as farnesoid x receptor modulators

Publications (1)

Publication Number Publication Date
MX2021009570A true MX2021009570A (en) 2021-09-08

Family

ID=69811924

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021009570A MX2021009570A (en) 2019-02-15 2020-02-14 Substituted bicyclic compounds as farnesoid x receptor modulators.

Country Status (7)

Country Link
AU (1) AU2020221370A1 (en)
BR (1) BR112021015963A2 (en)
CA (1) CA3129533A1 (en)
EA (1) EA202192263A1 (en)
MX (1) MX2021009570A (en)
SG (1) SG11202108796YA (en)
WO (1) WO2020168148A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL293892A (en) 2020-01-15 2022-08-01 Inserm Institut National De La Sant? Et De La Rech M?Dicale Use of fxr agonists for treating an infection by hepatitis d virus
US20240100125A1 (en) 2021-01-14 2024-03-28 Enyo Pharma Synergistic effect of a fxr agonist and ifn for the treatment of hbv infection
TW202308629A (en) 2021-04-28 2023-03-01 法商Ｅｎｙｏ製藥公司 Strong potentiation of tlr3 agonists effects using fxr agonists as a combined treatment
CN115340536A (en) * 2021-05-13 2022-11-15 华东理工大学 Amide compound containing 1,2, 4-oxadiazole and salt thereof, preparation method and application

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4383177B2 (en) 2002-03-01 2009-12-16 スミスクライン ビーチャム コーポレーション hPPAR activator
US7189712B2 (en) 2002-10-10 2007-03-13 Smithkline Beecham Corporation 1,3-Oxazole compounds for the treatment of cancer
US8716321B2 (en) 2005-04-08 2014-05-06 Ptc Therapeutics, Inc. Methods for dosing an orally active 1,2,4-oxadiazole
WO2008011130A2 (en) 2006-07-21 2008-01-24 Takeda Pharmaceutical Company Limited Amide compounds
EP2917203B1 (en) 2012-11-02 2019-04-03 Dana-Farber Cancer Institute, Inc. Method for identifying myc inhibitors
CN106661056B (en) 2014-06-19 2019-07-05 百时美施贵宝公司 As Casein kinase 1 δ/epsilon inhibitor Imidazopyridazine derivative
US10208573B2 (en) 2014-09-10 2019-02-19 Halliburton Energy Services, Inc. Perforating gun with integrated retaining system
CA3056019A1 (en) * 2017-03-15 2018-09-20 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
JP7174709B2 (en) * 2017-03-15 2022-11-17 メタクリン，インク． Farnesoid X receptor agonists and uses thereof

Also Published As

Publication number Publication date
EA202192263A1 (en) 2022-01-27
BR112021015963A2 (en) 2021-10-05
CA3129533A1 (en) 2020-08-20
SG11202108796YA (en) 2021-09-29
WO2020168148A1 (en) 2020-08-20
AU2020221370A1 (en) 2021-10-07

Similar Documents

Publication Publication Date Title
MX2021009570A (en) Substituted bicyclic compounds as farnesoid x receptor modulators.
MX2021009694A (en) Substituted bicyclic compounds as farnesoid x receptor modulators.
EA202091063A1 (en) BRIDGE BICYCLIC COMPOUNDS AS PHARNESOID X-RECEPTOR MODULATORS
EA201991127A1 (en) CYCLOBUTANE AND AZETIDINE CONTAINING MONO AND SPYROCYCLIC COMPOUNDS AS INTEGRIN αV INHIBITORS
EA202091084A1 (en) Alkenic spirocyclic compounds as modulators of pharnesoid X-receptors
EA202091101A1 (en) SPIROCYCLIC COMPOUNDS AS MODULATORS OF THE PHARNESOID X-RECEPTOR
EA201991122A1 (en) 3-SUBSTITUTED PROPANIC ACIDS AS AN INTEGRIN INHIBITORS αV
ZA202101960B (en) Protein tyrosine phosphatase inhibitors
CR20210501A (en) Protein tyrosine phosphatase inhibitors
MX2019005233A (en) Pyrrole amides as alpha v integrin inhibitors.
EA201991123A1 (en) INDAZOLE DERIVATIVES AS ANTEGRIN ANTAGONISTS αV
MX2021015935A (en) Salt forms of bempedoic acid and methods for using the same.
MX2019005234A (en) Azole amides and amines as alpha v integrin inhibitors.
PE20170946A1 (en) 2-AMINO-6- (DIFLUOROMETIL) - 5,5-DIFLUORO-6-PHENYL-3,4,5,6-TETRAHYDROPYRIDINES AS BACE1 INHIBITORS
MX2022001784A (en) Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents.
MX2019011844A (en) Process for preparation of sulfonyl carbamate bile acid derivatives.
MX2021003706A (en) Treating essential tremor using (r)-2-(4-isopropylphenyl)-n-(1-(5 -(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamide.
MX2021009424A (en) Substituted amide compounds useful as farnesoid x receptor modulators.
EA202092253A1 (en) SUBSTITUTED IMIDAZOLIDIN-2-ONE DERIVATIVES AS PRMT5 INHIBITORS
ECSP19072975A (en) PYRAZOLE [1,5-A] PYRIMIDINE DERIVATIVES REPLACED WITH PHARMACOLOGICALLY ACTIVE ALLICYCLICS
MX2021009564A (en) Substituted amide compounds useful as farnesoid x receptor modulators.
EA201891038A1 (en) MUSCARINE RECEPTOR 4 ANTAGONISTS AND METHODS OF THEIR APPLICATION
EA202190801A1 (en) PROTEIN TYROSIN PHOSPHATASE INHIBITORS
MX2022005912A (en) 1,8-naphthyridin-2-one compounds for the treatment of autoimmune disease.